Recce Pharmaceuticals (ASX:$RCE) Receives Advanced Overseas Finding

Recce Pharmaceuticals Ltd (ASX:RCE) has been awarded an AU$11,172,377 Advanced Overseas Finding by the Australian Government's AusIndustry for its Synthetic Anti-Viral Research & Development (R&D) applicable expenditure. This finding extends the 43.5% R&D rebate to cover the company's activities worldwide for a period of three years, affirming the national interest in Recce's R&D endeavors.

Executive Commentary on Advanced Overseas Finding

Recce Pharmaceuticals CEO James Graham expressed gratitude for the Australian Government's recognition of the company's anti-infective programs, emphasizing Recce's leadership in combating the global-health threat of anti-microbial resistant superbugs.

Summary of Advanced Overseas Finding for Recce Pharmaceuticals

Recce Pharmaceuticals Ltd (ASX:RCE) has been awarded an AU$11,172,377 Advanced Overseas Finding by the Australian Government's AusIndustry for its Synthetic Anti-Viral Research & Development (R&D) applicable expenditure. This finding extends the 43.5% R&D rebate to cover the company's activities worldwide for a period of three years, affirming the national interest in Recce's R&D endeavors. The finding ensures that the Australian Government will provide the company R&D rebates as non-dilutive cash when claimed or drawn proportionately through R&D funding facilities. CEO James Graham expressed gratitude for the recognition, highlighting the importance of Recce's anti-infective programs in addressing global health challenges. Recce Pharmaceuticals is developing a New Class of Synthetic Anti-Infectives to combat antibiotic-resistant superbugs and emerging viral pathogens, with a pipeline including patented, broad-spectrum, synthetic polymer anti-infectives. The company's anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses, presenting a promising solution to existing antibiotic challenges. Recce's automated manufacturing supports its present clinical trials, aiming to exploit the unique capabilities of its technologies targeting unmet medical needs.